T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$3.11B |
| 2 |
Meta Platforms (Facebook)
META
|
+$2.59B |
| 3 |
EQT Corp
EQT
|
+$1.31B |
| 4 |
Colgate-Palmolive
CL
|
+$1.08B |
| 5 |
Adobe
ADBE
|
+$1.06B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.92B |
| 2 |
UnitedHealth
UNH
|
+$1.78B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.55B |
| 4 |
Ross Stores
ROST
|
+$1.54B |
| 5 |
ASML
ASML
|
+$1.49B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.61% |
| 2 | Healthcare | 16.91% |
| 3 | Consumer Discretionary | 11.05% |
| 4 | Financials | 10.6% |
| 5 | Communication Services | 9.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TCS
2626
DELISTED
THE CONTAINER STORE GROUP, INC.
TCS
| $135K | ﹤0.01% |
2,850
-377
| -12% | -$16.8K |
|
|
DX
2627
Dynex Capital
DX
$3.23B
| $134K | ﹤0.01% |
10,621
-3,115
| -23% | -$36.4K |
|
2628
MacroGenics
MGNX
$259M
| $134K | ﹤0.01% |
24,977
+234
| +0.9% | +$1.44K |
|
2629
Applied Digital
APLD
$8.81B
| $133K | ﹤0.01% |
14,131
+1,454
| +11% | +$8.67K |
|
|
IVAC
2630
DELISTED
Intevac Inc
IVAC
| $133K | ﹤0.01% |
35,215
+9,115
| +35% | +$48.9K |
|
2631
SoundHound AI
SOUN
$3.32B
| $130K | ﹤0.01% |
+28,378
| New | +$84.4K |
|
|
TIO
2632
DELISTED
Tingo Group, Inc. Common Stock
TIO
| $130K | ﹤0.01% |
107,162
+24,862
| +30% | +$56.1K |
|
2633
SIGA Technologies
SIGA
$207M
| $129K | ﹤0.01% |
25,395
+397
| +2% | +$2.26K |
|
2634
Codexis
CDXS
$175M
| $128K | ﹤0.01% |
45,653
+1,395
| +3% | +$4.51K |
|
2635
Rigel Pharmaceuticals
RIGL
$762M
| $128K | ﹤0.01% |
9,887
-1,395
| -12% | -$18.9K |
|
|
GRTS
2636
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $127K | ﹤0.01% |
64,735
+17,835
| +38% | +$41.8K |
|
|
BFX
2637
DELISTED
BowFlex Inc.
BFX
| $127K | ﹤0.01% |
103,300
| – | – |
|
|
KYNB
2638
Kyntra Bio
KYNB
$28.5M
| $126K | ﹤0.01% |
1,852
-30,493
| -94% | -$12.6M |
|
|
PRPH
2639
DELISTED
ProPhase Labs
PRPH
| $126K | ﹤0.01% |
+1,730
| New | +$141K |
|
2640
Planet Labs
PL
$8.82B
| $125K | ﹤0.01% |
38,690
+1,961
| +5% | +$7.77K |
|
|
YMAB
2641
DELISTED
Y-mAbs Therapeutics
YMAB
| $125K | ﹤0.01% |
18,282
-6,441
| -26% | -$48.3K |
|
2642
Atara Biotherapeutics
ATRA
$76.7M
| $124K | ﹤0.01% |
3,065
+70
| +2% | +$3.96K |
|
2643
Beam Global
BEEM
$25.5M
| $124K | ﹤0.01% |
11,900
| – | – |
|
2644
Dyne Therapeutics
DYN
$4.85B
| $124K | ﹤0.01% |
10,943
-280,367
| -96% | -$3.31M |
|
2645
RPC Inc
RES
$1.39B
| $124K | ﹤0.01% |
17,243
+3,297
| +24% | +$24.1K |
|
2646
Curis
CRIS
$3.91M
| $123K | ﹤0.01% |
369
| – | – |
|
|
FPI
2647
Farmland Partners
FPI
$425M
| $123K | ﹤0.01% |
+10,030
| New | +$112K |
|
|
PTRA
2648
DELISTED
Proterra Inc. Common Stock
PTRA
| $123K | ﹤0.01% |
102,308
-9,100
| -8% | -$11.2K |
|
2649
Karyopharm Therapeutics
KPTI
$45.1M
| $122K | ﹤0.01% |
4,541
+510
| +13% | +$22K |
|
2650
Natural Gas Services Group
NGS
$474M
| $122K | ﹤0.01% |
12,288
| – | – |
|
Similar funds
T. Rowe Price Associates's Q2 2023 Portfolio in Review
As of Q2 2023, T. Rowe Price Associates held 3,044 positions worth $718B, up 7.4% from $668B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2023 filing shows 123 new, 1,636 increased, 968 reduced and 150 closed positions. Its largest new stake was Kenvue: 26,317,608 shares worth $695M. The largest sale was Microsoft, an estimated $1.92B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2023 buy was Kenvue: 26,317,608 shares worth $695M.
- T. Rowe Price Associates added most to Amazon in Q2 2023, an estimated $3.11B increase.
- T. Rowe Price Associates's biggest Q2 2023 reduction was Microsoft, cutting an estimated $1.92B.
- T. Rowe Price Associates fully exited Canadian Natural Resources in Q2 2023, selling an estimated $112M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $718B portfolio in Q2 2023.
- T. Rowe Price Associates opened 123 new positions and closed 150 in Q2 2023.
- T. Rowe Price Associates's portfolio value rose 7.4% quarter-over-quarter to $718B.
Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.